Pharvaris Business Model Canvas

KOLs in allergy/immunology (HAE prevalence ~1:50,000) guide trial design and endpoints for Pharvaris, ensuring regulatory-aligned outcomes. Academic HAE centers accelerate recruitment and real-world insights, shortening site activation and improving data quality. Multidisciplinary advisory boards refine dosing strategies and patient-reported outcomes, building clinical credibility and clear adoption pathways.

Key partnerships (CROs, CMOs, KOLs, patient groups, payers, specialty distributors) enable rapid multi-country HAE trials, GMP scale-up, regulatory-aligned endpoints and payer-ready evidence. HAE prevalence ~1:50,000 guides recruitment strategies. Pharma CMO market >$80B in 2024; specialty medicines >40% of US drug spend.

In 2024 Pharvaris is scaling CMC and supply chain by optimizing API synthesis and oral formulation robustness, aligning development with ICH Q2(R1) analytical validation and ICH Q1A(R2) stability requirements. Processes, stability and packaging are being validated through commercial-scale batches and real-time stability studies. Dual-source strategies and supplier audits mitigate single‑point failures. Launch readiness includes inventory buffering and QA/QC systems for batch release.

Design and run Phase 2/3 pivotal trials (50–300 patients per trial); adaptive designs can shorten timelines by ~30%. Prepare IND (FDA 30-day), NDA (PDUFA 10mo standard/6mo priority) and resolve CMC/clinical queries; scale CMC with dual sourcing for launch. Medical affairs/HEOR drive MSLs, RWE and payer strategies targeting ~20–30k global HAE patients (prevalence 1:50,000 in 2024).

Trusted CRO, CMO and distributor relationships compress development and supply cycles, crucial for a clinical-stage HAE player where disease prevalence is ~1 in 50,000. KOL and advocacy ties provide clinical insight and patient access that accelerate enrollment and real-world evidence generation. Early payer contacts—top 10 US payers covering roughly 70% of insured lives—enable value dialogues before launch. These connections materially speed execution and de-risk commercialization.

Proprietary B2 receptor program with robust IP and supporting preclinical and clinical datasets for oral small‑molecule antagonists.

Experienced rare disease team using US 7‑year and EU 10‑year exclusivity, GCP processes and regulatory workflows to de‑risk approvals.

Established CRO/CMO/KOL/payer network; HAE prevalence ~1 in 50,000; top‑10 US payers cover ~70%; 2024 access to equity and nondilutive funding to complete pivotal studies.

Consistent oral dosing aims to lower attack frequency, with prophylactic HAE therapies showing real-world attack reductions commonly reported between 50–80% and ER visit decreases up to 60% in 2024 observational datasets; predictable exposure supports routine prevention, may cut rescue-medication use substantially, and enhances productivity by reducing missed workdays and improving daily functioning.

Pill-based on-demand and prophylaxis for HAE (prevalence ~1:50,000; ≈160,000 global) enables rapid self-management (median time-to-relief ~2h), improves adherence (~+20%), and cuts attacks 50–80% with ER visits down up to 60% (2024 RWD); HEOR and value-based contracts support favorable formulary access.

Collaborate with payers and HTAs via transparent dossiers and shared outcomes data—critical for HAE where prevalence is about 1:50,000 (≈160,000 patients globally), enabling robust real-world evidence generation.

Offer budget-impact and scenario-modeling sessions to quantify cost offsets and forecast uptake across treated populations.

Run pilots for outcomes-based contracting and hold regular KPI-driven reviews to sustain access and reimbursement.

Dedicated MSL education and CME sustain KOL ties in HAE (prevalence ~1:50,000; ≈160,000 global), patient hubs, copay support and omni-channel coaching boost adherence; 2024 surveys: ~70% improved control, 40% higher platform-driven adherence. Payer pilots and outcomes contracting with KPI reviews maintain reimbursement; site initiatives target 30-day payment turnaround.

Small, expert sales teams call on allergists and immunologists to build deep specialist relationships and referral pathways. HAE affects roughly 1 in 50,000 people, enabling data-driven targeting of high-volume HAE centers and networks. In-office education and controlled sample programs where appropriate accelerate uptake and reinforce Pharvaris scientific differentiation.

Specialty pharmacy limited distribution concentrates dispensing and care coordination for HAE (prevalence ~1 in 50,000; ~6,600 US, ~160,000 worldwide, 2024). No cold-chain simplifies logistics; embedded pharmacist counseling and centralized hub support adherence. E-prescribing (Surescripts 2024: ~85% routed electronically), telehealth and targeted specialist sales drive uptake via hospital formularies and congress-driven KOL visibility.

Payers and PBMs, which collectively manage roughly 80% of US prescription benefits, evaluate Pharvaris on coverage and total cost of care; specialty drugs already account for over 50% of US drug spending. They demand robust HEOR, budget‑impact models and outcomes guarantees tied to adherence and clinical results. As access gatekeepers, their contracting decisions dictate market uptake and pricing cadence.

HAE patients (~1:50,000; ~6,000 diagnosed US, 2024) seek oral acute and prophylactic options prioritizing rapid relief and convenience. Allergists/immunologists drive initiation, needing robust efficacy/safety data. Payers/PBMs (cover ~80% US benefits) focus on HEOR, budget impact and outcomes-linked contracting. Global rare disease market (~300M patients; >50 countries orphan frameworks, 2024).

Regulatory and compliance costs include submission preparation, agency fees and consultancy support—biotech submission budgets often run $5–40M across IND/NDA phases, with US FDA user fees ~ $3.2M (FY2024) for a standard application and consultancy retainers of $250k–$1M. Pharmacovigilance systems and safety reporting infrastructure typically require $0.5–2M initial investment plus 15–20% annual maintenance. GxP training and audit programs cost ~$50k–300k per site annually. Ongoing label and risk-management activities add $1–3M per year for small/ mid‑cap companies.

Clinical development dominates costs (Phase 2 $30–60M; Phase 3 $100–200M in 2024). CMC/manufacturing ~20–30% of development budgets; validation/stability programs cost millions annually. Regulatory/submission $5–40M; FDA user fee ~$3.2M (FY2024). G&A $3–8M/year for small caps; monitoring/audits ~20–30% of trial budgets.

Upfronts and development milestones generate near-term cash via multi-million-dollar upfronts and staged milestone payments tied to regional regulatory and sales goals. Co-development or co-promotion structures let Pharvaris share clinical and commercial costs while retaining upside through royalties. Shared risk and commercialization leverage accelerate market access by aligning partner capabilities. Royalties on partnered territories typically run mid-single to low-double digit percentages.

On‑demand HAE sales priced at orphan levels (prevalence ~1 in 50,000) plus specialty pharmacy rebates; prophylactic maintenance yields recurring lifetime value; upfronts/milestones and mid‑single to low‑double digit royalties; PRV sale potential: tens–hundreds MM USD; orphan tax credit 25% reduces dev cost.